Safety profile of abatacept in rheumatoid arthritis: A review

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1855-1870

  Khraishi, Majed ^a,b   Russell, Anthony ^c   Olszynski, Wojciech P ^d  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Nexus Clinical Research Inc   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Abatacept; Arthritis; Biologic agents; Rheumatoid; Safety

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; ARTHRALGIA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INFLUENZA; MALIGNANT NEOPLASTIC DISEASE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; PHARYNGITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; METHOTREXATE;

EID: 78649365879     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.011     Document Type: Review

References (44)

1. Lee DM, Weinblatt ME Rheumatoid arthritis. Lancet. 2001, 358:903-911.
2. Kvien TK Epidemiology and burden of illness of rheumatoid arthritis. PharmacoEconomics. 2004, 22(SUPPL 1):1-12.
3. Sokka T, Abelson B, Pincus T Mortality in rheumatoid arthritis: 2008 Update. Clin Exp Rheumatol. 2008, 26(SUPPL 51):S35-S61.
4. Gabriel SE Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008, 121(SUPPL 1):S9-S14.
5. Orencia (abatacept) [package insert] 2009, Bristol-Myers Squibb Company, Princeton, NJ.
6. Orencia (abatacept) [package insert] 2009, Bristol-Myers Squibb Canada, Montreal, Canada.
7. Orencia (abatacept) [package insert] 2010, Bristol-Myers Squibb Pharma EEIG, Uxbridge, UK.
8. AJ Ostör Abatacept: A T-cell co-stimulation modulator for the treatment of rheumatoid arthritis [published correction appears in Clin Rheumatol. 2008;27:1477]. Clin Rheumatol 2008, 27:1343-1353.
9. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46:1470-1479.
10. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006, 144:865-876.
11. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial [published correction appears in Arthritis Rheum. 2005;52:3321]. Arthritis Rheum. 2005, 52:2263-2271.
12. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo- controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008, 67:1096-1103.
13. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008, 58:953-963.
14. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition [published correction appears in N Engl J Med. 2005;353:2311]. N Engl J Med. 2005, 353:1114-1123.
15. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheu- matoid arthritis and an inadequate response to antitumour necrosis factor therapy. Ann Rheum Dis. 2008, 67:547-554.
16. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999, 103:1243-1252.
17. Safety and efficacy of abatacept versus placebo in subjects with psoriatic arthritis Accessed February 1, 2010. http://www.clinicaltrials.gov/ct2/results?term=NCT00534313.
18. Efficacy and safety study of abatacept to treat lupus nephritis Accessed February 1, 2010. http://clinicaltrials.gov/ct2/results?term=NCT00430677.
19. Sibilia J, Westhovens R Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25(SUPPL 46):S46-S56.
20. Simon TA, Smitten A, Meng M, et al. Serious infections in the rheumatoid arthritis abatacept clinical development program: An updated epidemiological assessment. Ann Rheum Dis. 2007, 66(SUPPL 2). 20. Abstract SAT0032.
21. Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: An epidemiological assessment. Ann Rheum Dis. 2009, 68:1819-1826.
22. Smitten AL, Qi K, Simon TA, Becker JC Autoimmune adverse events in the abatacept RA clinical development program: A safety analysis with ≥10,000 person-years of exposure. Arthritis Rheum. 2008, 58(SUPPL 9):S786. Abstract 1673.
23. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis. 2007, 66:228-234.
24. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349:1907-1915.
25. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006, 54:2807-2816.
26. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexatenaive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009, 68:1870-1877.
27. Schiff MH, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann Rheum Dis. 2009, 68:1708-1714.
28. Kremer J, Russell A, Emery P, et al. Abatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-naive patients with RA. Arthritis Rheum. 2007, 56(SUPPL 9):S300. Abstract FRI0263.
29. Westhovens R, Kremer J, Emery P, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologicnaive patients with RA. Ann Rheum Dis. 2008, 67(SUPPL 2):341. Abstract SAT0108.
30. Schiff M, Keiserman M, Codding C, et al. Two-year efficacy and safety in abatacept-treated patients with RA who received continuous therapy or switched from infliximab to abatacept. Ann Rheum Dis. 2009, 68(SUPPL 3):575. Abstract SAT0103.
31. Weinblatt M, Keystone E, Combe B, et al. Safety and patient-reported outcomes through 2 years of treatment with abatacept in rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): The ASSURE trial. Arthritis Rheum. 2006, 54(SUPPL):248-249. Abstract 106.
32. Remicade (infliximab) [package insert] 2009, Centocor Ortho Biotech, Malvern, Pa.
33. Khraishi M Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol SUPPL. 2009, 82:25-32.
34. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and metaanalysis of rare harmful effects in randomized controlled trials [published correction appears in JAMA. 2006;295:2482]. JAMA 2006, 295:2275-2285.
35. Keystone EC Safety of biologic therapies-an update. J Rheumatol SUPPL. 2005, 74:8-12.
36. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008, 59:762-784. American College of Rheumatology.
37. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995, 2:561-572.
38. Winthrop KL Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006, 2:602-610.
39. Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases [published correction appears in Ann Rheum Dis. 2009;68:452]. Ann Rheum Dis. 2008, 67(SUPPL 3):iii2-iii25.
40. Askling J, Bongartz T Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008, 20:334-339.
41. Humira (adalimumab) [package insert] 2009, Abbott Laboratories, North Chicago, Ill.
42. Haggerty HG, Abbott MA, Reilly TP, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007, 34:2365-2373.
43. Østensen M, Förger F Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009, 5:382-390.
44. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate therapy. Ann Rheum Dis. 2004, 63:1062-1068. 990145 Study Group.